Piper Jaffray Starts Sutro Biopharma (STRO) at Overweight

Piper Jaffray analyst Edward Tenthoff initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Overweight rating and a price target of $23.00.

The analyst likes the revolutionary XpressCF platform, the potential upside from STRO-001 Phase 1 data in 2019, benefits from STRO-002 advancing into Clinic and the validating partnerships.

For an analyst ratings summary and ratings history on Sutro Biopharma click here. For more ratings news on Sutro Biopharma click here.

Shares of Sutro Biopharma closed at $14.53 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• New Street Research Upgrades Micron Technology (MU) to Buy